Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,283 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Fountain Valley, CaliforniaAges 18 years+ - NCT06787456Recruiting
Screening for nasopharyngeal cancer in residents
This study is screening residents aged 30-69 for nasopharyngeal cancer (NPC). It aims to detect cancer early through regular check-ups and follow-up.
Zhuhai, GuangdongAges 30–69 - NCT05595434Recruiting
Studying stress and reality tracking in young adults
This study looks at how people track what’s real and how stress affects thinking and behavior. It may help researchers understand stress-related changes, using tasks involving listening and reading.
BronAges 18–30 - NCT06772025Recruiting
Understanding kidney injury after heart surgery with heart-lung machine
This study looks at why some people develop kidney damage after heart surgery that uses a heart-lung machine. It aims to help doctors better predict and prevent this complication.
Bad Oeynhausen, North Rhine-WestphaliaAges 18 years+ - NCT06772623RecruitingPhase 1/Phase 2
Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
Phoenix, ArizonaAges 18 years+ - NCT06778447Recruiting
Trial of disc tissue injection for degenerative disc disease
This study tests an experimental treatment that injects donated disc tissue (called an allograft) into damaged discs in your lower back. It's designed for people with chronic low back pain from disc degeneration who haven't found relief from non-surgical treatments.
Napa, CaliforniaAges 22–85 - NCT06780137RecruitingPhase 1/Phase 2
Gocatamig plus ifinatamab deruxtecan for advanced small cell lung cancer
This study tests two new drugs (gocatamig and ifinatamab deruxtecan) for people whose small cell lung cancer has spread or come back after standard chemotherapy. It aims to see if the combination works better than current options.
Aurora, ColoradoAges 18 years+ - NCT06781567RecruitingPhase 2
HG146 for advanced adenoid cystic carcinoma
This trial tests a new drug called HG146 for people with advanced adenoid cystic carcinoma that has progressed despite previous treatments. The goal is to see if HG146 can slow or stop the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06780085RecruitingPhase 2
Study of new drugs for advanced lung cancer
This trial tests new treatments for people with stage IV nonsquamous non-small cell lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It aims to find better options for those whose cancer has specific genetic features.
Lexington, KentuckyAges 18 years+ - NCT06780098RecruitingPhase 2
Study of new treatments for advanced squamous lung cancer
This trial tests new drugs for people with advanced squamous non-small cell lung cancer that has gotten worse after standard treatments like immunotherapy and chemotherapy. The goal is to find better options for those who need them.
Lexington, KentuckyAges 18 years+ - NCT06760819RecruitingPhase 2
Sevacertinib for solid tumors with HER2 mutations
This study tests an oral tablet called sevacertinib in people with solid tumors (not lung cancer) that have a HER2 mutation. It aims to see how well the drug works and how safe it is for people who have tried other treatments or have no good options left.
Birmingham, AlabamaAges 18 years+ - NCT06764706Recruiting
Risankizumab for moderate-to-severe ulcerative colitis
This study observes how well risankizumab works for people with moderate to severe ulcerative colitis who are already starting it as part of their regular care. It helps doctors learn more about the drug's real-world effects.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06764316RecruitingPhase 1
Safety study of BAY 3547926 for advanced liver cancer
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
Dothan, AlabamaAges 18 years+ - NCT06764771RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.
Hackensack, New JerseyAges 18 years+ - NCT06765668RecruitingPhase 4
Study of CREXONT for Parkinson's with wearing-off episodes
This study tests how well CREXONT, an extended-release form of carbidopa-levodopa, controls symptoms in people with Parkinson's who experience predictable 'off' periods when their regular medication wears off. The goal is to see if it can reduce the daily hours of poor mobility.
Phoenix, ArizonaAges 18 years+ - NCT06764693Recruiting
Study on treatment with Risankizumab for psoriatic arthritis
This study tests how well a medicine called Risankizumab works for people with psoriatic arthritis. It is for adults who have had symptoms for at least 6 months and have not had enough help from at least one other arthritis medicine.
Quilmes, Buenos AiresAges 18–75 - NCT06045910RecruitingPhase 1/Phase 2
A study of ALETA-001 for certain B-cell blood cancers
This trial tests a new treatment called ALETA-001 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments, including CAR T-cell therapy. It aims to see if ALETA-001 can help when standard options have not worked.
BirminghamAges 16 years+ - NCT06758505Recruiting
Stroke recovery study: social activities after stroke
This study tests a rehabilitation program to help people who have had a stroke get back to the social activities they enjoyed before. If you have trouble joining in activities with family or friends, this program may help you reconnect.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06754852RecruitingPhase 1/Phase 2
Study of HMB-002 for von Willebrand disease
This study tests a new medicine called HMB-002 for people with von Willebrand disease. It aims to see if the drug can help control bleeding without needing regular preventive treatments.
Phoenix, ArizonaAges 16–69 - NCT06752668RecruitingPhase 2
Testing ORX750 for narcolepsy and idiopathic hypersomnia
This trial tests an experimental drug called ORX750 for people with narcolepsy or idiopathic hypersomnia. You would need to stop your current sleepiness medicines to see if ORX750 helps reduce daytime sleepiness.
Auburn, AlabamaAges 18–65 - NCT06750094RecruitingPhase 3
Study of amivantamab plus FOLFIRI in colorectal cancer
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
Chandler, ArizonaAges 18 years+ - NCT06751238RecruitingPhase 1
Secukinumab for children with psoriatic arthritis
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
Loma Linda, CaliforniaAges 2–17 - NCT06752681RecruitingPhase 1
Testing day301 for advanced solid tumors
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT06759649RecruitingPhase 1
Study of COM503 for advanced solid tumors
This trial tests a new drug called COM503 for people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. It aims to see if the drug is safe and how well it works.
New Haven, ConnecticutAges 18 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,283 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.